Synopsis:
Mankind Pharma Ltd, remained in focus after announcing a Rs. 797 crore acquisition to strengthen its women’s health portfolio. The strategic buyout, executed through a slump sale, underscores the company’s focus on expanding branded generics in the high-growth female health segment, bolstering its domestic leadership position.
A pharmaceutical stock traded steady after unveiling plans to acquire a major women’s health generics business. The move highlights the company’s ongoing strategy to expand in high-margin therapeutic categories and sustain growth momentum amid strong domestic demand in the healthcare sector.
Mankind Pharma Ltd, with a market capitalization of Rs. 1,00,869.92 crore, opened at its high of Rs. 2,476.15 against the previous close of Rs. 2,458.85, marking a rise of 0.70 percent from the previous close.
What’s the News?
Mankind Pharma Limited has executed a Business Transfer Agreement (BTA) with Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. Under this agreement, the company will acquire BSV’s Branded Generic Business related to the Women’s Health Rx Portfolio on a going concern basis by way of slump sale for a total consideration of Rs. 797 crore, subject to closing adjustments.
As per the terms, 50 percent of the sale consideration will be paid on the closing date defined in the BTA, while the balance amount will be payable within 150 days from the closing date. The completion of the acquisition remains subject to customary pre-conditions, closing actions, and other terms specified in the agreement.
Also Read: Bulk Deal: 2 Stocks in which Plutus Wealth Management bought 3.75 lakh shares worth ₹91.68 Cr
Financial Snapshot
Quarter-on-Quarter (QoQ) Performance, Mankind Pharma’s consolidated sales increased from Rs. 3,079 crore to Rs. 3,570 crore, up 15.93 percent. Operating profit rose from Rs. 683 crore to Rs. 847 crore, a growth of 24.04 percent.
Profit before tax (PBT) improved from Rs. 511 crore to Rs. 540 crore, up 5.68 percent, while net profit grew from Rs. 425 crore to Rs. 445 crore, registering a 4.71 percent increase.
Year-on-Year (YoY) Performance, On a yearly basis, sales rose from Rs. 2,868 crore to Rs. 3,570 crore, reflecting a 24.48 percent growth. Operating profit improved from Rs. 672 crore to Rs. 847 crore, up 26.04 percent. However, PBT declined from Rs. 666 crore to Rs. 540 crore, down 18.92 percent, while net profit dropped from Rs. 543 crore to Rs. 445 crore, marking a 18.04 percent decline.
About the Company
Mankind Pharma Ltd, is one of India’s largest pharmaceutical companies with a strong focus on the domestic market. Operating across pharmaceutical formulations and consumer healthcare, Mankind provides quality and affordable products across a broad therapeutic spectrum, including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN, and respiratory segments.
In the consumer healthcare business, it holds leading brands in condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamins, and anti-acne preparations. Following the acquisition of BSV’s women’s health portfolio, Mankind has reinforced its position as a key player in this segment.
The company has around 18,000 field professionals, reaches over five lakh doctors nationwide, and operates 30 manufacturing facilities in India. Backed by seven R&D centers and more than 770 scientists, Mankind continues to drive product innovation across dosage forms such as tablets, capsules, syrups, vials, and OTC products.
Written By Manan Gangwar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
